Public Health Ontario | Santé publique Ontario

SURVEILLANCE REPORT

COVID-19 Vaccine Uptake in Ontario: December 14, 2020 to June 18, 2023

This report describes vaccine uptake using data extracted from the Ontario Ministry of Health's COVaxON application. Data in this report includes the most current information extracted from COVaxON as of June 19, 2023 at approximately 7:00 a.m., and describes vaccinations reported up to June 18, 2023.

Please visit the interactive Ontario COVID-19 Data Tool to explore COVID-19 vaccination uptake data by public health unit, age group and trends over time.

As of February 3, 2023, PHO moved to monthly reporting of COVID-19 vaccine information. This report is updated **every four weeks**.

Background

The COVID-19 vaccination program began in Ontario on December 14, 2020. Currently, all individuals in the province 6 months of age and older are eligible for a complete series of a Health Canada (HC) authorized COVID-19 vaccine, and all individuals 5 years of age and older are eligible for at least one booster dose.[1] Bivalent COVID-19 vaccine products became available on September 12, 2022 and are recommended as a booster dose at a 6 month interval for individuals 5 years of age and older who have not yet received a booster dose (monovalent or bivalent) since September 1, 2022.[1] As of April 6, 2023, high-risk individuals are further recommended to receive an additional booster dose of a bivalent COVID-19 vaccine product as part of Ontario's spring booster program.[1]

Definition of Terms

As vaccine program eligibility varies by age, the following defintions are used to describe vaccine uptake among individuals **5 years of age and older** (eligible for a bivalent booster):

- **Completed primary series and any booster dose over 12 months ago** refers to individuals that have completed their primary series and have received any number of booster doses (e.g. first booster, second booster) of HC-authorized COVID-19 vaccine over 12 months ago.
- **Completed primary series and any booster dose 6 to less than 12 months ago** refers to individuals that have completed their primary series and have received any number of booster doses (e.g. first booster, second booster) of HC-authorized COVID-19 vaccine 6 to less than 12 months ago.
- **Completed primary series and any booster dose within the previous 6 months** refers to individuals that have completed their primary series and have received any number of booster doses (e.g. first booster, second booster) of HC-authorized COVID-19 vaccine within the previous 6 months.

The definitions used to describe vaccine uptake among individuals **under 5 years of age** are described in the Technical Notes.

Highlights

- To date, 3,553,393 bivalent COVID-19 vaccine doses have been administered in Ontario among individuals 5 years of age and older (Table 1a). Since April 6th, 2023, 328,717 bivalent COVID-19 vaccine doses have been administered in Ontario among individuals 5 years of age and older who already received at least one bivalent COVID-19 vaccine dose (e.g., spring high risk program) (Table 1b).

- 6.8% of individuals 5 years of age and older who completed their primary series have received any booster dose in the previous 6 months (Figure 3, Table 2).

    - The proportion of individuals that completed their primary series and received any booster dose in the previous 6 months increases with age. Over 21% of adults 70 years of age and older received any booster dose in the previous 6 months (Figure 3, Table 2).

    - 19.5% of individuals 5 years of age and older who completed their primary series received any booster dose 6 to less than 12 months ago. While 27.4% of individuals 5 years of age and older received any booster dose over 12 months ago and 31.0% of individuals 5 years of age and older completed their primary series but have received no booster doses (Figure 3, Table 2).

- To date, 5.1% of children under 5 years of age have completed their primary series (Figure 4, Table 3).

Doses Administered Over Time

Figure 1. Number of COVID-19 vaccine doses administered by dose number and week of dose administration: Ontario



Note:

1. Individuals with seventh doses include immunocompromised individuals who have received an extended 3-dose primary series and a fourth booster (i.e. dose 7).

Figure 2. Number of COVID-19 vaccine doses administered by vaccine product and week of dose administration: Ontario



Table 1a. Number of bivalent COVID-19 vaccine doses administered by dose number and product among individuals 5 years of age and older: Ontario, September 12, 2022 to June 18, 2023

Bivalent COVID-19 vaccine product	Age (years)	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Total
Moderna Spikevax Bivalent BA.1	**6-11**	0	1	22	2	2	0	0	27
	12-17	31	9	197	360	26	0	0	623
	18-29	1,714	458	6,732	43,367	3,292	48	3	55,614
	30-39	1,578	446	6,688	81,856	10,856	192	3	101,619
	40-49	840	279	5,106	94,835	13,172	268	11	114,511
	50-59	882	286	5,962	147,170	27,393	502	19	182,214
	60-69	1,229	406	6,357	117,598	168,601	3,034	59	297,284
	70-79	859	364	4,210	69,643	220,071	4,569	41	299,757
	80+	398	252	2,464	36,317	160,373	2,701	13	202,518
	Total: 6+	**7,531**	**2,501**	**37,738**	**591,148**	**603,786**	**11,314**	**149**	**1,254,167**
Pfizer-BioNTech Comirnaty Bivalent BA.4/5	**5-11**	216	172	16,913	4,675	30	0	0	22,006
	12-17	765	308	25,376	49,901	1,266	23	0	77,639
	18-29	6,017	1,490	21,408	99,005	23,857	978	36	152,791
	30-39	4,187	1,090	16,087	114,287	39,150	2,047	74	176,922
	40-49	2,362	655	11,823	126,805	45,473	2,961	117	190,196
	50-59	2,597	690	12,294	190,353	85,995	5,919	187	298,035

Bivalent COVID-19 vaccine product	Age (years)	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Total
	60-69	2,862	960	10,627	155,609	281,266	59,796	599	511,719
	70-79	1,711	659	5,474	84,941	289,107	118,857	759	501,508
	80+	659	325	2,579	40,742	151,115	67,784	387	263,591
	Total: 5+	**21,376**	**6,349**	**122,581**	**866,318**	**917,259**	**258,365**	**2,159**	**2,194,407**
Moderna Spikevax Bivalent BA.4/5	**18-29**	75	21	343	403	482	116	1	1,441
	30-39	75	23	246	847	1,477	523	14	3,205
	40-49	43	11	160	673	1,631	661	34	3,213
	50-59	37	21	162	968	2,761	1,424	42	5,415
	60-69	63	41	194	1,156	5,579	16,622	145	23,800
	70-79	39	36	146	962	5,729	30,290	208	37,410
	80+	33	40	175	943	4,756	24,280	108	30,335
	Total: 18+	**365**	**193**	**1,426**	**5,952**	**22,415**	**73,916**	**552**	**104,819**

Notes:

1. Bivalent COVID-19 vaccine products are authorized and recommended as booster doses. These products are not typically expected to be administered as a primary series, and may represent data errors or missing/incomplete data.
2. Individuals 5-11 years of age are only recommended to receive the pediatric product of Pfizer-BioNTech Comirnaty Bivalent BA.4/5 COVID-19 vaccine as a booster dose. Individuals 6-11 years of age are only recommended to receive the pediatric dose of Moderna Spikevax Bivalent BA.1 COVID-19 vaccine as a booster dose.

Table 1b. Number of bivalent COVID-19 vaccine doses administered by dose number and product among individuals 5 years of age and older who already received at least one bivalent COVID-19 vaccine dose (e.g., spring high risk program): Ontario, April 6, 2023 to June 18, 2023

Bivalent COVID-19 vaccine product	Age (years)	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Total
Moderna Spikevax Bivalent BA.1	**6-11**	0	0	0	0	0	0	0
	12-17	1	0	0	2	0	0	3
	18-29	0	0	1	6	5	0	12
	30-39	2	0	1	17	14	0	34
	40-49	0	0	0	23	19	0	42
	50-59	1	1	1	60	56	1	120
	60-69	1	0	6	103	597	7	714
	70-79	0	0	9	117	1,102	5	1,233
	80+	1	0	5	78	661	2	747
	Total: 6+	**6**	**1**	**23**	**406**	**2,454**	**15**	**2,905**
Pfizer-BioNTech Comirnaty Bivalent BA.4/5	**5-11**	6	1	12	11	0	0	30
	12-17	1	1	66	502	11	0	581
	18-29	24	11	54	949	629	18	1,685
	30-39	29	13	49	1,463	1,230	45	2,829
	40-49	18	7	39	1,724	1,787	66	3,641

Bivalent COVID-19 vaccine product	Age (years)	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Total
	50-59	25	6	75	3,444	4,014	106	7,670
	60-69	38	35	263	6,104	48,657	379	55,476
	70-79	73	53	464	7,401	100,493	502	108,986
	80+	35	31	257	3,686	58,118	280	62,407
	Total: 5+	**249**	**158**	**1,279**	**25,284**	**214,939**	**1,396**	**243,305**
Moderna Spikevax Bivalent BA.4/5	**18-29**	3	0	14	237	103	1	358
	30-39	10	2	18	594	490	13	1,127
	40-49	3	3	19	699	616	28	1,368
	50-59	5	3	31	1,307	1,332	36	2,714
	60-69	20	11	110	2,429	15,882	136	18,588
	70-79	23	8	186	2,791	29,117	190	32,315
	80+	26	20	152	2,247	23,489	103	26,037
	Total: 18+	**90**	**47**	**530**	**10,304**	**71,029**	**507**	**82,507**

Notes:

1. Bivalent COVID-19 vaccine products are authorized and recommended as booster doses. These products are not typically expected to be administered as a primary series, and may represent data errors or missing/incomplete data.
2. Individuals 5-11 years of age are only recommended to receive the pediatric product of Pfizer-BioNTech Comirnaty Bivalent BA.4/5 COVID-19 vaccine as a booster dose. Individuals 6-11 years of age are only recommended to receive the pediatric dose of Moderna Spikevax Bivalent BA.1 COVID-19 vaccine as a booster dose.
3. Individuals recommended for the spring booster program include: individuals 65 years of age and older, individuals residing in congregate living settings for seniors or congregate care settings for people with complex medical care needs, pregnant individuals, immunocompromised individuals 18 years of age and older, and individuals 55 years of age and older who identify as First Nations, Inuit or Metis (as well as their household members 55 years of age and older). [1]

Vaccination coverage

Individuals 5 years of age and older (i.e., eligible for bivalent booster)

Figure 3. Provincial coverage estimates among individuals 5 years of age and older by age group: Ontario, December 14, 2020 to June 18, 2023



Table 2. Number of individuals 5 years of age and older who completed their primary COVID-19 vaccine series and coverage estimates by booster dose status and age group: Ontario, December 14, 2020 to June 18, 2023

Age (years)	Number of individuals: No booster dose(s)	Number of individuals: Any booster dose 12+ months ago	Number of individuals: Any booster dose 6 to <12 months ago	Number of individuals: Any booster dose <6 months ago	Coverage (%): No booster dose(s)	Coverage (%): Any booster dose 12+ months ago	Coverage (%): Any booster dose 6 to <12 months ago	Coverage (%): Any booster dose <6 months
5-11	330,145	105	55,703	20,201	30.5	<0.1	5.1	1.9
12-17	545,075	99,974	80,335	21,168	55.5	10.2	8.2	2.2
18-29	1,102,174	727,408	218,168	55,961	43.4	28.6	8.6	2.2
30-39	828,377	666,727	282,810	66,122	38.7	31.1	13.2	3.1
40-49	634,818	661,879	307,440	67,440	33.9	35.3	16.4	3.6
50-59	518,744	713,955	452,962	103,651	26.0	35.8	22.7	5.2
60-69	319,976	594,475	630,044	219,275	17.2	31.9	33.8	11.8
70-79	122,984	309,158	491,456	261,034	10.0	25.3	40.2	21.3
80+	53,847	172,114	285,902	158,277	7.8	24.9	41.4	22.9
Total: 5+	**4,456,140**	**3,945,795**	**2,804,820**	**973,129**	**31.0**	**27.4**	**19.5**	**6.8**

Individuals under 5 years of age

Figure 4. Provincial COVID-19 vaccine coverage estimates among individuals under 5 years of age: Ontario



Note:

1. Children 0-6 months of age are included in denominators used to calculate coverage estimates, but are not eligible for COVID-19 vaccination.

Table 3. Number of individuals who received a COVID-19 vaccine and coverage estimates among individuals under 5 years of age: Ontario, December 14, 2020 to June 18, 2023

Age (years)	Number of individuals: Initiated primary series	Number of individuals: Completed primary series	Coverage (%): At least one dose	Coverage (%): Completed primary series
<5	22,292	37,251	8.1	5.1

Notes:

1. Children 0-6 months of age are included in denominators used for calculate coverage estimates, but are not eligible for COVID-19 vaccination.

Technical Notes

Definition of Terms

Vaccine series refers to the number of vaccine doses that are needed to complete a primary series. COVID-19 vaccine products currently approved by Health Canada (HC) and the World Health Organization (WHO) Emergency Use Listing have a two-dose (i.e. Moderna Spikevax, Pfizer-BioNTech Comirnaty, AstraZeneca Vaxzevria/COVISHIELD, Novavax Nuvaxovid, Covaxin, Sinopharm, CoronaVac) or one-dose (i.e. Janssen Jcovden, Convidecia) schedule. For children under 5 years of age, Health Canada has also approved a Pfizer-BioNTech Comirnaty three-dose schedule.

Interval refers to the period of time (e.g. number of days) between doses. For all available COVID-19 vaccines, there is a recommended minimum number of days that an individual must wait between doses of a primary series or between booster dose(s).

Initiated primary series refers to individuals that have received only one dose of a two-dose COVID-19 vaccine series, whether it is HC/WHO-authorized or not, or two doses of a non-HC/non-WHO authorized vaccine. For some children under 5 years of age, this refers to individuals that have received only one or two doses of a three-dose Pfizer-BioNTech Comirnaty vaccine series.

Completed primary series refers to individuals that have received:

- One dose of a one-dose HC/WHO-authorized vaccine (i.e. dose one of one),
- Both doses of a two-dose HC/WHO-authorized vaccine series (i.e. dose two of two) including series with mixed HC/WHO-authorized vaccine products,
- One dose of non-HC/non-WHO authorized vaccine and one dose of HC/WHO-authorized vaccine,
- Three doses of any other combination of HC/WHO-authorized vaccines and non-HC/non-WHO authorized vaccines,
- For some children under 5 years of age, this refers to individuals that have received three doses of a three-dose Pfizer-BioNTech Comirnaty vaccine series.

Completed primary series and one booster dose refers to individuals that have completed their primary series (as per the definition above) and have received a booster dose of a HC-authorized vaccine. Note: a dose of WHO-authorized or non-HC/non-WHO authorized vaccine is not considered a booster dose.

Coverage estimate (at least one dose) refers to the proportion of the population that has received at least one dose of any COVID-19 vaccine, whether it is HC/WHO-authorized or not.

Coverage estimate (completed primary series) refers to the proportion of the population that has completed their primary series, as per the definition above.

Coverage estimate (completed primary series and one booster dose) refers to the proportion of the population that has completed their primary series (as per the above definition) and received a booster dose of a HC-authorized vaccine.

Data Sources

- COVID-19 vaccination data were based on information successfully extracted from the Ontario Ministry of Health's COVaxON application as of **June 19, 2023 at approximately 7:00 a.m**.

- Ontario population estimate data were sourced from the Ministry of Finance.[2]

Data Caveats

- Data presented may differ from other sources for various reasons, including differing extract times and methodologies for processing COVaxON data.

- COVaxON is a dynamic reporting system, which allows ongoing updates to data previously entered. As a result, data extracted from COVaxON represents a snapshot at the time of extraction and may differ from previous or subsequent reports.

- The data represent vaccination information reported in COVaxON. As a result, all counts may be subject to varying degrees of underreporting due to a variety of factors.

- Due to the expanding vaccine program, which now includes single-dose primary series and booster dose options, vaccine terminology has been updated (e.g. "fully vaccinated" has been updated to "completed primary series") and may not align with other sources. For certain populations (e.g. immunocompromised individuals) three doses are recommended to complete the primary series. Due to challenges in identifying these individuals in the COVaxON data, it was not possible to account for some three-dose primary series in the analysis, and these individuals are classified as per the definitions above.

    - Individuals with seventh doses are likely immunocompromised individuals that received an extended 3-dose primary series and a fourth booster (i.e. a seventh dose)

- Counts reported for doses administered will not align with the number of individuals vaccinated for the following reasons:

    - Counts for the number of doses administered in Ontario exclude doses administered out of province and from non-Ontario stock. However, individuals that received a vaccination out of province or from non-Ontario stock are included in coverage estimates

    - Counts for the number of individuals vaccinated and coverage estimates exclude individuals reported as deceased. However, doses administered to individuals later reported as deceased are included in dose counts.

    - Methods for calculating age differ when reporting on doses administered in the province and vaccinated individuals/coverage estimates. For doses administered, the date of dose administration is used to calculate age and age is interpreted as the age at the time of each dose administration. For individuals vaccinated and coverage estimates the date of data extraction is used to calculate age and age is interpreted as the individual's current age.

- Coverage estimates shown as 100% may represent estimates of 100% or more. Coverage estimates may be over 100% due to limitations in the vaccination data (numerator) or Ontario population estimates (denominator).

- Children 0-6 months of age are included in denominators used to calculate coverage estimates for the <5 age group. However, children 0-6 months of age not eligible for COVID-19 vaccination and therefore are not included in the numerator.

Vaccination Data Processing

- Data includes clients with a dose administration record recorded in COVaxON, which captures a small number of client records with a residential postal code outside of Ontario who may be eligible for vaccination on the basis of working in a high-risk setting (e.g. long-term care home) in Ontario.

- Non-valid dose records are excluded. Non-valid records include doses where the status is reported as 'entered in error', 'invalid', or other similar variations, as well as doses where the status is valid (e.g. 'administered') but that are identified as non-valid client records (e.g. client first and last name were reported as 'test', 'do not use', 'error', 'ignore', or other similar variations).

- For missing dose administration dates and dose administration dates prior to December 14, 2020, the date the administration record was created is used as a proxy.

- Duplicate dose administration records (i.e. clients with multiple dose administration records with the same date) are identified and excluded using personal identifiers, such as health card number, name, date of birth, and postal code, where available, as well as dose administration date.

- After removing duplicate dose administration records, dose number is assigned based on the dose administration dates reported. Dose administration date is also used to determine the dose interval.

    - For clients with multiple doses reported with different administration dates, the first chronological dose is considered the first dose.

    - To determine a date for the second dose, the first subsequent dose administered on or after the product-specific recommended minimum interval of the first dose product, with a 4-day grace period, is used. Doses administered prior to the product-specific recommended minimum interval, with a 4-day grace period, are not considered valid. For example, if there are two subsequent doses that were 7 days and 21 days from a Moderna Spikevax COVID-19 vaccine first dose, respectively, then the dose that is 21 days from the first dose is used as the second dose. Similarly, if there are two subsequent doses that are 10 days and 12 days from the first dose, respectively, then neither dose is used and the individual is not assigned a second dose. The recommended product specific minimum intervals, with a 4-day grace period, as outlined by the National Advisory Committee on Immunization (NACI) are as follows (there is currently no maximum interval for second doses, i.e., no recommendation to restart a vaccine series regardless of the length of delay of the second dose):

        - Pfizer-BioNTech Comirnaty COVID-19 vaccine: 15 days (19 days with a 4-day grace period).[3]

        - Moderna Spikevax COVID-19 vaccine: 17 days (21 days with a 4-day grace period).[3]

        - AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine: 24 days (28 days with a 4-day grace period).[3]

        - Novavax Nuvaxovid COVID-19 vaccine: 17 days (21 days with a 4-day grace period).[3]

        - Janssen Jcovden, Moderna Spikevax Bivalent BA.1, Moderna Spikevax Bivalent BA.4/5, Pfizer-BioNTech Comirnaty Bivalent BA.4/5, WHO-authorized, non-HC/non-WHO authorized vaccine products or unspecified/missing products: 17 days (21 days with a 4-day grace period).

    - To determine a date for the third dose, the first subsequent dose administered 28 days or more after the second dose is used, regardless of the HC-authorized vaccine product administered for the second dose (i.e. the dose 3 interval is not product-specific). If multiple doses 28 days or more after the second dose are reported, then the first chronological dose after the second dose is used.

    - To determine dates for the fourth to seventh doses, the first subsequent date 56 days or more after the date of the previous dose is used, regardless of the HC-authorized vaccine product administered for the previous dose (i.e. the minimum interval is not product-specific). If multiple doses 56 days or more after the previous dose are reported, then the first chronological dose after the previous dose is used.

- A maximum of seven doses are assigned for an individual.

- Only HC-authorized vaccine products are considered for booster doses.

- Age at the time of dose administration and age at the time of data extraction are calculated using the client date of birth and the date of dose administration or date of data extraction, respectively. Ages reported as >=120 years, <0 years, or where date of birth is missing are considered unknown. In Canada, the Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines are authorized for use in individuals aged 6 months and older.[4] The AstraZeneca Vaxzevria/COVISHIELD and Janssen Jcovden COVID-19 vaccines are authorized for use in individuals aged 18 years and older.[4] The Novavax Nuvaxovid COVID-19 vaccine is authorized for use in individuals aged 12 years and older. [4] The Moderna Spikevax Bivalent BA.1 COVID-19 vaccine is authorized for use as a booster in individuals aged 6 years and older.[3-4] The Pfizer-BioNTech Comirnaty Bivalent BA.4/5 COVID-19 vaccine is authorized for use as a booster in individuals aged 5 years and older.[3] The Moderna Spikevax Bivalent BA.4/5 COVID-19 vaccine is authorized as a booster dose for individuals aged 18 years and older.[3] Individuals 5-11 years of age are only recommended to receive the pediatric product of Pfizer-BioNTech Comirnaty Bivalent BA.4/5 COVID-19 vaccine as a booster dose, and individuals 6-11 years of age are only recommended to receive the pediatric dose of Moderna Spikevax Bivalent BA.1 COVID-19 vaccine as a booster dose.[3] Based on expected vaccine product use as per NACI and product monographs, clients under 6 months of age that received the Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines, clients under 18 years of age that received the AstraZeneca Vaxzevria/COVISHIELD, Janssen Jcovden, and Moderna Spikevax Bivalent BA.4/5 COVID-19 vaccines, clients under 12 years of age that received the Novavax Nuvaxovid COVID-19 vaccine, clients under 6 years of age that received the Moderna Spikevax Bivalent BA.1 vaccine, and clients under 5 years of age that received the Pfizer-BioNTech Comirnaty Bivalent BA.4/5 COVID-19 vaccine are considered to have unknown age.

- Clients reporting a gender of ‘Non-binary/third gender’ and ‘Other’ are combined into an ‘Other’ category. ‘Unknown’ gender included clients where gender is reported as ‘Prefer not to say’, ‘Unknown’, or where gender was missing.

Vaccination Data Analysis and Reporting

- Out of province dose administration records well as doses administered from non-Ontario stock (e.g. doses from federal stock for populations such as the Armed Forces) are included in coverage estimates. However, out of province and non-Ontario stock dose administration records are not included in dose counts.

- Dose numbers are maintained in doses administered counts. For example, if an individual received doses 1 and 2 out of province and a third dose in Ontario, the third dose is counted as a dose 3 administered in Ontario and the first two doses are not counted as they were administered out of province.

- Clients reported as deceased are excluded when describing the number of individuals vaccinated and in coverage estimates, but are included when describing doses administered in the province.

- Age at the time of dose administration (e.g. age at dose 1, age at dose 2, etc.) is used when describing doses administered in Ontario.

- Age at the time of data extraction is used when describing the number of individuals vaccinated and in coverage estimates.

- Clients with unknown age/gender are excluded for age/gender specific analyses, but are included in provincial totals.

- Dose records where the product is reported as other/unknown/missing are excluded from product-specific analysis, but are included in provincial totals.

- Pfizer-BioNTech Comirnaty vaccine product counts and Moderna Spikevax COVID-19 vaccine product counts include infant (<5 years of age), pediatric (5-11 years of age), and 12+ years of age doses. Pfizer-BioNTech Comirnaty Bivalent BA.4/5 vaccine product counts include pediatric and 12+ years of age doses. Moderna Spikevax Bivalent BA.1 vaccine product counts include pediatric and 12+ years of age doses.

- 180 days is used as the 6-month interval and 360 days is used as the 12-month interval for booster dose status.

- Data are shown using the date of dose one administration for coverage estimates for at least one dose; the date the primary series was completed for completed primary series counts and coverage estimates; and the date the first booster dose was received for completed primary series and one booster counts and coverage estimates.

References

1. Ontario. Ministry of Health. COVID-19 vaccines [Internet]. Toronto, ON: King's Printer for Ontario; 2022 [modified 2023 Apr 18; cited 2023 Apr 24]. Available from: https://ontario.ca/page/covid-19-vaccines

2. Population Reporting. Population Projections Public Health Unit, 2021-2046 [data file]. Toronto, ON: Ministry of Finance [producer]; Toronto, ON: Ontario. Ministry of Health, IntelliHealth Ontario [distributor]; [data extracted 2022 Jan 13].

3. Public Health Agency of Canada; National Advisory Committee on Immunization. Part 4 - Active vaccines In: Canadian immunization guide [Internet]. Evergreen ed. Ottawa, ON: Government of Canada; 2022 [modified 2022 Dec 22; cited 2023 Jan 13]. Table 1: Immunization schedule for a primary series, by COVID-19 vaccine. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html

4. Health Canada. Approved COVID-19 vaccines [Internet]. Ottawa, ON: Government of Canada; 2022 [modified 2022 Aug 05; cited 2023 Jan 13]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html

Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 vaccine uptake in Ontario: December 14, 2020 to June 18, 2023. Toronto, ON: King's Printer for Ontario; 2023.

Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication. The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use. This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information, email ivpd@oahpp.ca.

Ontario